{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:32:59Z","timestamp":1793147579656,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:00:00Z","timestamp":1793145600000},"content-version":"vor","delay-in-days":114,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01515-8","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:56:29Z","timestamp":1783310189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine"],"prefix":"10.1038","volume":"11","author":[{"given":"Chaitanya","family":"Kurhade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin R.","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey T.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Babiarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Iris","family":"Cadima Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Munoz Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirada","family":"Suphaphiphat Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayvon","family":"Modjarrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2024.7395","volume":"331","author":"Y Xie","year":"2024","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024. JAMA 331, 1963\u20131965 (2024).","journal-title":"JAMA"},{"key":"1515_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59344-7","volume":"16","author":"HJ Appaneal","year":"2025","unstructured":"Appaneal, H. J. et al. Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System. Nat. Commun. 16, 4033 (2025).","journal-title":"Nat. Commun."},{"key":"1515_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae695","volume":"11","author":"H Kopel","year":"2024","unstructured":"Kopel, H. et al. Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States. Open Forum Infect. Dis. 11, ofae695 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"1515_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofag019","volume":"13","author":"SY Tartof","year":"2026","unstructured":"Tartof, S. Y., Frankland, T. B., Slezak, J. M., Ackerson, B. K. & Puzniak, L. Effectiveness and durability of the BNT162b2 KP.2 vaccine against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults. Open Forum Infect. Dis. 13, ofag019 (2026).","journal-title":"Open Forum Infect. Dis."},{"key":"1515_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S2213-2600(23)00306-5","volume":"11","author":"SY Tartof","year":"2023","unstructured":"Tartof, S. Y. et al. Effectiveness of BNT162b2 BA.4\/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Lancet Respir. Med. 11, 1089\u20131100 (2023).","journal-title":"Lancet Respir. Med."},{"key":"1515_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae370","volume":"11","author":"SY Tartof","year":"2024","unstructured":"Tartof, S. Y. et al. Effectiveness of BNT162b2 XBB vaccine against XBB and JN.1 sublineages. Open Forum Infect. Dis. 11, ofae370 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"1515_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53842-w","volume":"15","author":"AR Caffrey","year":"2024","unstructured":"Caffrey, A. R. et al. Effectiveness of BNT162b2 XBB vaccine in the US veterans affairs healthcare system. Nat. Commun. 15, 9490 (2024).","journal-title":"Nat. Commun."},{"key":"1515_CR8","unstructured":"FDA. COVID-19 Vaccines (2025-2026 Formula) for Use in the United States Beginning in Fall 2025, https:\/\/www.fda.gov\/vaccines-blood-biologics\/industry-biologics\/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025 (2025)."},{"key":"1515_CR9","unstructured":"FDA. Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024, <https:\/\/www.fda.gov\/vaccines-blood-biologics\/updated-covid-19-vaccines-use-united-states-beginning-fall-2024> (2024)."},{"key":"1515_CR10","unstructured":"FDA. Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the U.S, <https:\/\/www.fda.gov\/media\/169591\/download#:~:text=Based%20on%20the%20totality%20of,vaccines%20with%20a%20monovalent%20XBB.> (2023)."},{"key":"1515_CR11","unstructured":"Thornburg, N. J. 2024-2025 Update on Current Epidemiology of COVID-19 and SARS-CoV-2 Genomics, https:\/\/www.fda.gov\/media\/186593\/download (2025)."},{"key":"1515_CR12","unstructured":"W.H.O. WHO TAG-VE Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: XFG, <https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/epp\/tracking-sars-cov-2\/25062025_xfg_ire.pdf?sfvrsn=260a9981_4> (2025)."},{"key":"1515_CR13","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1473-3099(25)00308-1","volume":"25","author":"C Guo","year":"2025","unstructured":"Guo, C. et al. Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1. Lancet Infect. Dis. 25, e374\u2013e377 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1515_CR14","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/S1473-3099(25)00015-5","volume":"25","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1. Lancet Infect. Dis. 25, e128\u2013e130 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1515_CR15","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S1473-3099(25)00079-9","volume":"25","author":"L Chen","year":"2025","unstructured":"Chen, L. et al. Virological characteristics of the SARS-CoV-2 LP.8.1 variant. Lancet Infect. Dis. 25, e193 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1515_CR16","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1016\/S1473-3099(24)00298-6","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect. Dis. 24, e416 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1515_CR17","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(23)00813-7","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. 24, e82 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1515_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65896-5","volume":"16","author":"W Chen","year":"2025","unstructured":"Chen, W. et al. Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2Adapted COVID-19 vaccines. Nat. Commun. 16, 10914 (2025).","journal-title":"Nat. Commun."},{"key":"1515_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01013-9","volume":"9","author":"K Modjarrad","year":"2024","unstructured":"Modjarrad, K. et al. Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine. NPJ Vaccines 9, 229 (2024).","journal-title":"NPJ Vaccines"},{"key":"1515_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","volume":"630","author":"CY Liang","year":"2024","unstructured":"Liang, C. Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950\u2013960 (2024).","journal-title":"Nature"},{"key":"1515_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2024.02.017","volume":"57","author":"TS Johnston","year":"2024","unstructured":"Johnston, T. S. et al. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity 57, 912\u2013925 e914 (2024).","journal-title":"Immunity"},{"key":"1515_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-022-05644-7","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521\u2013529 (2023).","journal-title":"Nature"},{"key":"1515_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1126\/science.adc9127","volume":"378","author":"YJ Park","year":"2022","unstructured":"Park, Y. J. et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 378, 619\u2013627 (2022).","journal-title":"Science"},{"key":"1515_CR24","doi-asserted-by":"publisher","first-page":"101165","DOI":"10.1016\/j.lanmic.2025.101165","volume":"6","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2. Lancet Microbe 6, 101165 (2025).","journal-title":"Lancet Microbe"},{"key":"1515_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00772-8","author":"Y Kaku","year":"2026","unstructured":"Kaku, Y. et al. Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(25)00772-8 (2026).","journal-title":"Lancet Infect. Dis."},{"key":"1515_CR26","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/S1473-3099(25)00690-5","volume":"26","author":"C Happle","year":"2026","unstructured":"Happle, C. et al. Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation. Lancet Infect. Dis. 26, e3\u2013e5 (2026).","journal-title":"Lancet Infect. Dis."},{"key":"1515_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","volume":"3","author":"S Khare","year":"2021","unstructured":"Khare, S. et al. GISAID\u2019s role in pandemic response. China CDC Wkly 3, 1049\u20131051 (2021).","journal-title":"China CDC Wkly"},{"key":"1515_CR28","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/infdis\/jiad353","volume":"228","author":"N Lasrado","year":"2023","unstructured":"Lasrado, N. & Barouch, D. H. SARS-CoV-2 hybrid immunity: the best of both worlds. J. Infect. Dis. 228, 1311\u20131313 (2023).","journal-title":"J. Infect. Dis."},{"key":"1515_CR29","doi-asserted-by":"publisher","unstructured":"Appaneal, H. J. et al. Early effectiveness of the BNT162b2 LP.8.1 vaccine against COVID-19 emergency department, urgent care, and outpatient visits in the US Veterans Affairs Healthcare System. medRxiv, 2026.2001.2022.26344618 https:\/\/doi.org\/10.64898\/2026.01.22.26344618 (2026).","DOI":"10.64898\/2026.01.22.26344618"},{"key":"1515_CR30","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s40121-025-01185-4","volume":"14","author":"O Diya","year":"2025","unstructured":"Diya, O. et al. Safety and immunogenicity of monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 vaccine in adults: single-arm substudy from a Phase 2\/3 trial. Infect. Dis. Ther. 14, 1973\u20131987 (2025).","journal-title":"Infect. Dis. Ther."},{"key":"1515_CR31","doi-asserted-by":"publisher","first-page":"126869","DOI":"10.1016\/j.vaccine.2025.126869","volume":"52","author":"O Diya","year":"2025","unstructured":"Diya, O. et al. A phase 2\/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >\/=18 years old. Vaccine 52, 126869 (2025).","journal-title":"Vaccine"},{"key":"1515_CR32","doi-asserted-by":"publisher","unstructured":"Gayed, J. et al. Safety and immunogenicity of the monovalent Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals >\/=12 Years Old: A Phase 2\/3 Trial. Vaccines 12, https:\/\/doi.org\/10.3390\/vaccines12020118.","DOI":"10.3390\/vaccines12020118"},{"key":"1515_CR33","doi-asserted-by":"publisher","unstructured":"Gayed, J. et al. Immunogenicity of the monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 vaccine against XBB.1.5, BA.2.86, and JN.1 sublineages: A Phase 2\/3 Trial. Vaccines 12, https:\/\/doi.org\/10.3390\/vaccines12070734.","DOI":"10.3390\/vaccines12070734"},{"key":"1515_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa2213082","volume":"388","author":"P Winokur","year":"2023","unstructured":"Winokur, P. et al. Bivalent Omicron BA.1-adapted BNT162b2 booster in adults older than 55 years. N. Engl. J. Med. 388, 214\u2013227 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1515_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag026","author":"P Winokur","year":"2026","unstructured":"Winokur, P. et al. Safety and immunogenicity of a fourth dose of Omicron-BA.1-adapted BNT162b2 COVID-19 vaccines in adults 18\u201255 years old. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciag026 (2026).","journal-title":"Clin. Infect. Dis."},{"key":"1515_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115543","volume":"44","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. Cell Rep. 44, 115543 (2025).","journal-title":"Cell Rep."},{"key":"1515_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116715","volume":"44","author":"IA Mellis","year":"2025","unstructured":"Mellis, I. A. et al. Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants. Cell Rep. 44, 116715 (2025).","journal-title":"Cell Rep."},{"key":"1515_CR38","unstructured":"Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season, https:\/\/pj.jiho.jp\/article\/253137 (2025)."},{"key":"1515_CR39","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"1515_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21105\/joss.03773","volume":"6","author":"I Aksamentov","year":"2021","unstructured":"Aksamentov, I., Roemer, C., Hodcroft, E. B. & Neher, R. A. Nextclade: clade assignment, mutation calling and quality control for viral genomes. J. Open Source Softw. 6, 1\u20135 (2021).","journal-title":"J. Open Source Softw."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01515-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:46:53Z","timestamp":1793144813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01515-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01515-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are current or former employees of Pfizer or BioNTech and may, therefore, be respective shareholders. Pfizer and BioNTech participated in the design, analysis, and interpretation of the data as well as the writing of this report and the decision to publish. W.L., U.\u015e., K.A.S., and K.M. are inventors on patents related to COVID-19 vaccines. P.S.A. and U.\u015e. are inventors on patents related to RNA technology.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"200"}}